Predictive biomarkers in tumor treatment by blocking PD-1/PD-L1 pathway

doi:10.3760/cma.j.issn.1673-422X.2016.06.014

Abstract

Abstract: Identifying biomarkers predicting clinical response to treatment of PD1/PDL1 pathway blockade can guide patient selection and therapeutic individualization. Some researches have shown that patients with cancer will acquire better clinical effects by blocking PD-1/PD-L1 pathway whose characteristics include higher pretreatment expression of PD-L1 by tumor cells or tumor infiltrating immune cells, the massive infiltration of intratumoral CD8+ T cells, the high mutation frequency of tumor cell gene. These biomarkers are expected to become indicators which can select patients.

Key words: Neoplasms, Therapy, Biological markers, PD-1/PD-L1 pathway

Cui Jinyuan, Tao Kaixiong. Predictive biomarkers in tumor treatment by blocking PD-1/PD-L1 pathway[J]. Journal of International Oncology, 2016, 43(6): 452-454.

References

［1］ Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy［J］. J Clin Oncol, 2015, 33(17): 1974-1982. DOI: 10.1200/JCO.2014.59.4358.　［2］邵婧怡, 孙国平. 程序性死亡受体1及其配体在恶性肿瘤中的研究进展［J］. 国际肿瘤学杂志, 2015 (5): 358-360. DOI: 10.3760/cma.j.issn.1673422X.2015.05.010. ［3］ Keir ME, Butte MJ, Freeman GJ, et al. PD1 and its ligands in tolerance and immunity［J］. Annu Rev Immunol, 2008, 26: 677-704. DOI: 10.1146/annurev.immunol.26.021607.090331. ［4］施敏骅, 邢玉斐, 张增利, 等. 肺癌细胞中可溶性程序性死亡配体1的表达及其对T细胞功能的影响［J］. 中华肿瘤杂志, 2013, 35(2): 85-88. DOI: 10.3760/cma.j.issn.02533766.2013.02.002. ［5］ Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape［J］. Sci Transl Med, 2012, 4(127): 127ra37. DOI: 10.1126/scitranslmed.3003689. ［6］ Tumeh PC, Harview CL, Yearley JH, et al. PD1 blockade induces responses by inhibiting adaptive immune resistance［J］. Nature, 2014, 515(7528): 568-571. DOI: 10.1038/nature13954. ［7］ Dong H, Strome SE, Salomao DR, et al. Tumorassociated B7H1 promotes Tcell apoptosis: a potential mechanism of immune evasion［J］. Nat Med, 2002, 8(8): 793-800. DOI: 10.1038/nm730. ［8］ Azuma T, Yao S, Zhu GF, et al. B7H1 is a ubiquitous antiapoptotic receptor on cancer cells［J］. Blood, 2008, 111(7): 3635-3643. DOI: 10.1182/blood-2007-11-123141. ［9］ Yang Y, Wu KE, Zhao E, et al. B7H1 enhances proliferation ability of gastric cancer stemlike cells as a receptor［J］. Oncol Lett, 2015, 9(4): 18331838. DOI: 10.3892/ol.2015.2949. ［10］ Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy［J］. Nat Rev Cancer, 2012, 12(4): 252-264. DOI: 10.1038/nrc3239. ［11］ Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the antiPDL1 antibody MPDL3280A in cancer patients［J］. Nature, 2014, 515(7528): 563-567. DOI: 10.1038/nature14011. ［12］ Philips GK, Atkins M. Therapeutic uses of antiPD1 and antiPDL1 antibodies［J］. Int Immunol, 2015, 27(1): 39-46. DOI: 10.1093/intimm/dxu095. ［13］ Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer［J］. N Engl J Med, 2012, 366(26): 2455-2465. DOI: 10.1056/NEJMoa1200694. ［14］ Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what′s here, what′s next?［J］. Curr Opin Immunol, 2015, 33(33): 23-35. DOI: 10.1016/j.coi.2015.01.006. ［15］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 24432454. DOI: 10.1056/NEJMoa1200690. ［16］ Wolchok JD. PD-1 blockers［J］. Cell, 2015, 162(5): 937. DOI: 10.1016/j.cell.2015.07.045. ［17］ Powles T, Eder JP, Fine GD, et al. MPDL3280A (antiPD-L1) treatment leads to clinical activity in metastatic bladder cancer［J］. Nature, 2014, 515(7528): 558-562. DOI: 10.1038/nature13904. ［18］ Swaika A, Hammond WA, Joseph RW. Current state of antiPDL1 and antiPD1 agents in cancer therapy［J］. Mol Immunol, 2015, 67(2 Pt A): 4-17. DOI: 10.1016/j.molimm.2015.02.009. ［19］ Lote H, Cafferkey C, Chau I. PD1 and PDL1 blockade in gastrointestinal malignancies［J］. Cancer Treat Rev, 2015, 41(10): 893903. DOI: 10.1016/j.ctrv.2015.09.004. ［20］ Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to antiPD-1 therapy［J］. Clin Cancer Res, 2014, 20(19): 5064-5074. DOI: 10.1158/1078-0432.CCR-13-3271. ［21］ Atefi M, Avramis E, Lassen A, et al. Effects of MAPK and PI3K pathways on PDL1 expression in melanoma［J］. Clin Cancer Res, 2014, 20(13): 34463457. DOI: 10.1158/10780432.CCR132797. ［22］ Rech AJ, Vonderheide RH. Dynamic interplay of oncogenes and T cells induces PDL1 in the tumor microenvironment［J］. Cancer Discov, 2013, 3(12): 1330-1332. DOI: 10.1158/21598290.CD-13-0775. ［23］ Brahmer JR, Drake CG, Wollner I, et al. Phase Ⅰ study of singleagent antiprogrammed death1 (MDX1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates［J］. J Clin Oncol, 2010, 28(19): 3167-3175. DOI: 10.1200/JCO.2009.26.7609. ［24］ Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes［J］. Nature, 2013, 499(7457): 214218. DOI: 10.1038/nature12213. ［25］ Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumourspecific mutant antigens［J］. Nature, 2014, 515(7528): 577-581. DOI: 10.1038/nature13988. ［26］ Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a Tcelldependent mechanism of cancer immunoediting［J］. Nature, 2012, 482(7385): 400-404. DOI: 10.1038/nature10755. ［27］ Fritsch EF, Rajasagi M, Ott PA, et al. HLAbinding properties of tumor neoepitopes in humans［J］. Cancer Immunol Res, 2014, 2(6): 522-529. DOI: 10.1158/2326-6066.CIR-13-0227. ［28］ Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD1 and inhibits T cell activation［J］. Nat Immunol, 2001, 2(3): 261-268. DOI: 10.1038/85330.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.